Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
accurate, agency, allocable, Alzheimer, analyzed, anomeric, Aptium, argument, arising, array, automobile, backbone, bearing, bile, blackout, bloodstream, branching, broaden, broadly, bypassing, calendar, categorize, cellular, CEO, chain, Chapter, charter, cholangiocarcinoma, clearance, clinicaltrial, constant, cured, cycle, davanat®, de, Debenture, deciphered, default, degradation, Description, diagnosed, diameter, duct, EMEA, enzymatic, evidencing, extraordinarily, factor, flat, galactomannan, galactose, Gene, Guar, gum, healthcare, incurrence, ineligibility, infection, inflammatory, inflow, isolated, Journal, kind, lapse, lectin, linkage, ll, lll, long, longest, lowest, mannose, men, microbial, open, orientation, overhead, owing, Oxley, partnership, payroll, PCT, penalty, petition, physiological, play, precautionary, precisely, receptor, RECIST, recovery, redemption, relevant, repay, replace, residue, secreted, shape, shareholder, shifted, shorter, shrinkage, signal, smallest, spending, stayed, subdivide, sum, summary, superceeded, suspend, Tetragonoloba, thereon, thereunder, translate, transmission, unacceptable, unambiguously, unavailable, understood, unpaid, unrecognized, untapped, USPTO, variation, vast, viral, women
Removed:
abnormal, absorption, achieved, acid, acquirer, acute, addressed, adhere, Adriamycin, affiliated, Alabama, anorexia, anticancer, apparent, avoid, bachelor, Bedford, bid, Birmingham, bladder, bleeding, bone, breathing, budgetary, buildup, capture, carcinoma, characterized, chemically, circulation, clear, collect, commencement, commitment, compatibility, contemplate, contracted, Cooperation, covering, cyclophosphamide, cytotoxic, Cytoxan, darkening, death, decreasing, deficiency, define, delivering, dense, deprivation, diarrhea, diet, dismissed, DNA, dramatically, drop, EDC, electronic, emotional, enabling, encouraging, enhance, enhancement, environment, envision, escalation, essentially, exclusively, extend, extending, extreme, fact, favorably, female, fluid, fluorinated, folinic, foregoing, forming, found, frequency, functional, Galactomycin, generic, genetic, Good, grow, Haifa, half, heart, hypersensitivity, immune, implanted, implement, improved, incorporate, index, individually, informal, inhibiting, injecting, injection, interact, interfere, investigation, kidney, killed, lessened, leukemia, Leverage, local, lymphoma, male, malignant, manage, marked, marrow, measuring, Medidata, melanoma, merger, metastasize, MIR, mortality, mouth, Nasdaq, negotiate, oral, Originally, ovarian, permeability, permit, Pharmacia, pharmacological, plasma, PLATINOL, predisposition, prescribed, PROH, proliferating, proven, PTO, pyrimidine, radioactive, ranging, rash, receiving, receptive, rectum, reformulate, Reformulation, regression, renal, rental, represented, resigned, respond, retail, reviewing, RNA, Roche, Russia, secondary, size, skin, SmallCap, smaller, smoking, sooner, speed, spouse, Standardization, stomach, strategy, studied, studying, suffering, superceded, suppression, survival, susceptible, system, systemic, Taxol, testicular, thyroid, tolerate, Toxikon, treated, unbalanced, uncontrolled, undergo, undesired, upgrade, upgraded, Upjohn, variety, Verify, vomiting, voting, Welfare, Wilmington, worldwide
Filing tables
Filing exhibits
Related press release
GALT similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-109887, 333-115118, 333-118907 and 333-111650 on Form S-3 and in Registration Statement Nos. 333-116629 and 333-109893 on Form S-8 of our report dated March 14, 2006, relating to the consolidated financial statements of Pro- Pharmaceuticals, Inc. appearing in this Annual Report on Form 10-K of Pro-Pharmaceuticals, Inc. for the year ended December 31, 2005.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 14, 2006